Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $85,554.36 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Mirum Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ:MIRM opened at $42.00 on Friday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $48.89. The company has a market capitalization of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98. The company has a fifty day moving average of $42.93 and a 200-day moving average of $40.62.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business’s quarterly revenue was up 89.4% on a year-over-year basis. During the same period last year, the company earned ($0.57) earnings per share. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIRM. State Street Corp raised its stake in shares of Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares during the last quarter. Rice Hall James & Associates LLC raised its position in Mirum Pharmaceuticals by 6.9% during the 2nd quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock worth $7,854,000 after purchasing an additional 14,843 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Mirum Pharmaceuticals by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after buying an additional 17,149 shares during the period. Geode Capital Management LLC grew its position in shares of Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Mirum Pharmaceuticals by 48.2% in the second quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock valued at $4,889,000 after buying an additional 46,506 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners increased their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.